Public funders and competitions
Grants, support programmes, awards. Detailed figures (scenarios, timeline) are available in the funder space.
Support the project
Support a Lille-born project against breast cancer.
Recanthia is at the very start of its story. Public funders, patrons, business angels, companies or individuals: here is what we need, what every euro will fund and how to join us.
Where we stand
The company is being set up and is not yet registered. We therefore cannot yet accept investment or issue tax receipts. Register your interest and we will come back to you as soon as the right framework is in place.
The need
€1M for 2027–2028.
To launch the B2B research services and mature the technology. The clinical programme will be funded later, from other sources.
How we will use the money
- Data & validation250 k€
Access to cohorts, analyses and independent biological validation.
- Founders’ salaries200 k€
Allow both co-founders to work full time on the project (employer costs included).
- Scientific hiring160 k€
Strengthen the team to deliver the first projects.
- Intellectual property90 k€
Protect the signature and the company’s developments.
- Quality & regulatory80 k€
Prepare quality requirements and the future clinical pathway.
- Infrastructure & tools60 k€
Computing, secure data storage and software.
- Business development40 k€
Meet and convince the first industry clients.
- Operations & insurance30 k€
Running costs of the future company.
- Reserve90 k€
Absorb quotation and execution variances.
Planned breakdown, November 2026. Salaries include employer costs. These amounts describe a need, not funding obtained.
What this funding enables
- 2027
Launch B2B: first pilot projects with industry on triple-negative disease and pembrolizumab, delivered reports, a reproducible analysis pipeline.
- 2028
Consolidate the evidence: independent cohorts, reproducibility, measured performance and limits of the signature.
Our business model
First: research
Services billed per project to pharma, biotechs and CROs. This revenue funds validation.
Then: the clinic
A decision-support tool, after clinical validation, approval and reimbursement.
Then: extension
Other treatments and other cancers treated with immunotherapy.
How to support us
Business angels and investors
Be the first to hear about the future fundraising, as soon as the company is created.
Patrons and companies
Financial or in-kind support (computing, data, expertise), or introductions through your network.
Scientific and clinical partners
Cohorts, expertise, validation: help us test the signature against clinical reality.
You can also simply spread the word
Share the key-facts page: one minute and one video to present the project.